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Abstract
Short-term randomised, controlled trials have found that dietary protein relative to carbohydrate can reduce blood pressure. Our objective
was to investigate the effects on blood pressure of an increase in protein intake from whey over 2 years in women aged over 70 years.
From the general population, 219 women aged between 70 and 80 years were recruited to a 2-year randomised, double-blind,
placebo-controlled parallel-design trial: 181 women completed the trial to the end of year 2. Participants were randomly assigned to
consume a daily whey protein-based beverage (protein) or an energy-matched low-protein high-carbohydrate beverage (control).
Blood pressure measurements were performed at baseline, year 1 and year 2. For protein relative to control, the estimated mean net
differences in protein and carbohydrate intakes were 18 (95 % CI 13, 23) and 222 (95 % CI 2 9, 2 35) g/d at year 1, and 22 (95 % CI
17, 28) and 2 18 (95 % CI 26, 2 31) g/d at year 2. Intention-to-treat analysis found no overall differences between groups in blood pressure
(P.0·5). Net differences in systolic and diastolic blood pressure were 2 2·3 (95 % CI 2 5·3, 0·7) and 21·5 (95 % CI 23·6, 0·6) mmHg at
year 1, and 1·6 (95 % CI 2 1·5, 4·7) and 0·3 (95 % CI 2 1·9, 2·4) mmHg at year 2. Similar differences in systolic and diastolic blood pressure
at years 1 and 2 were observed with per-protocol analysis. Therefore, the present study did not provide evidence that a higher whey protein intake in older women can have prolonged effects on blood pressure.
Key words: Protein: Blood pressure: Carbohydrate

Hypertension is the leading risk factor worldwide for total and
CVD mortality(1). Changes to diet and lifestyle within populations have been advocated as the major means of combating
hypertension. Several dietary and lifestyle modifications have
proven beneficial for reducing blood pressure(2), but the benefits of increasing total and/or animal-derived protein intake
remain contentious(3,4).
The role of protein intake in determining blood pressure
has been investigated in population studies and randomised
controlled trials. Approximately two-thirds of more than
twenty-five cross-sectional population studies report an inverse
relationship between estimated protein intake and blood
pressure(4 – 6). This inverse relationship appears to be more
robust for plant protein(3,4,7). However, several cross-sectional

studies, primarily in Asian populations, find an inverse association between animal protein intake specifically and blood
pressure(4). The relationship for both animal protein and plant
protein may be influenced by dietary and lifestyle factors associated with their intake, and with level of blood pressure.
Partial replacement of carbohydrate in the diet with protein
can lower blood pressure. A lower blood pressure with protein, derived from plant, mixed, or animal sources, compared
with carbohydrate has been demonstrated in several randomised controlled trials(8 – 12). Although results of cross-sectional
population studies suggest that plant protein may be superior
to animal protein, results of several trials indicate little difference between animal and plant proteins in their effects
on blood pressure(13 – 16). These studies suggest a beneficial
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effect on blood pressure of protein relative to carbohydrate,
and that type of protein may not be an important determinant
of effects.
However, the translation of the results of these studies into
population advice to manage blood pressure remains contentious. In many populations, advice to increase protein intake is
likely to result primarily in increases in the intake of animal
protein. There are few trials that have investigated the effects
of animal protein specifically, relative to carbohydrate(11).
In addition, there are few studies that have investigated
the longer-term effects of higher protein intakes on blood
pressure. Data from prospective studies(17 – 19) and longerterm randomised controlled trials(12,20), which may provide
a better indication of longer-term effects, remain limited.
Furthermore, there is some indication that the benefits of
protein on blood pressure may be larger in older individuals.
Therefore, the objective of the present trial was to investigate
the long-term effects on blood pressure, over 2 years, of an
increase in protein intake from whey in elderly women.

Methods
Participants
Study participants were recruited from the general population
between April and September 2007. A population-based
approach was used in which a random selection of women
(n 6065) aged 70 – 80 years on the electoral roll in Western
Australia received a letter inviting them to join the study.
Over 98 % of women of this age are on the Western Australian
electoral roll. Of the 829 women who responded to the letter,
256 attended clinic screening and 219 women who met the
inclusion criteria joined the study. The exclusion criteria
were: participation in another clinical trial during the previous
12 weeks; BMI . 35 kg/m2; clinical diagnosis of diabetes; history of gastrointestinal disease or disorder; clinical hepatic or
renal insufficiency; high protein intake as assessed by FFQ
(equivalent to protein intake more than 1·5 g/kg body
weight per d); lactose intolerance or unwillingness to consume milk products; previous osteoporotic fracture or metabolic bone disease apart from osteoporosis; currently or
within last year, taking medication for osteoporosis apart
from calcium or vitamin D; recent use of oral steroids; total
hip bone density more than 2 SD below the mean for their
age; cognitive impairment (Mini Mental State Score , 24);
and participants who, in the opinion of the investigator,
were not likely to complete the study for any reason. The
study population, women over 70 years, was chosen because
they are at increased risk of both hypertension and CVD;
effects of dietary factors to influence blood pressure in this
population could have a significant impact on risk of heart disease and stroke; and the effects of dietary protein on blood
pressure have yet to be investigated in older individuals.
All procedures followed were in accordance with institutional guidelines. The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved by
the Sir Charles Gairdner Hospital Human Research Ethics
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Committee. Written informed consent was obtained from
all subjects. The study was registered with the Australian
New Zealand Clinical Trials Registry (Registration no.
ACTRN012607000163404).

Design, randomisation and blinding
The study design was a 2-year randomised, double-blind, placebo-controlled trial. Eligible participants were randomised to
one of two treatment groups: protein or placebo (control).
Group allocation was achieved using a computer-generated
randomisation sequence with a block size of 10 to assign
participants to protein or control in a ratio of 1:1. The randomisation code was generated by one of the investigators
(C. W. B.), who did not have direct contact with the participants, and was kept at the School of Public Health, Curtin
University. Staff of Curtin University dispensed the powder
to participants in tins labelled only with subjects’ name and
study ID, which were delivered by courier to the participants
every 3 months. The study participants and researchers
responsible for assessment of outcome measures remained
blinded to the assignment individuals’ group. The code break
was applied after the outcome data had been entered into
electronic files.

Supplements
Participants consumed 250 ml/d of their assigned supplement
(beverage). The 250 ml high-protein beverage provided 30 g
of protein, 600 mg of calcium and 3·2 kJ/ml (810 kJ).
The 250 ml low-protein (control) beverage provided 2·1 g of
protein, 600 mg of calcium and 3·3 kJ/ml (820 kJ). The base
product for both beverages was skimmed milk. The high-protein
product had whey protein isolate (Alacen 894; Fonterra
Brands Limited, Balcatta, Western Australia, Australia) added,
while carbohydrate (maltodextrin) was used in the
low-protein (control) beverage to match for the energy. The
nutrient composition of the two supplements is presented in
Table 1. Alginate natural flavouring and natural emulsifying
agents were used to provide a similar texture and flavour to
the drinks. The supplements were provided to participants
as a powder which was reconstituted to 250 ml with cold
water before consumption. To aid in adherence, the participants were provided with a diary in which they marked the
consumption of the product. To validate this consumption, a
count was made of empty tins and those that contained
unused powder returned at the clinic visit at the end of year
1 and year 2.
Table 1. Nutrient composition of the supplements
(per 250 ml daily intake)

Energy (kJ)
Protein (g)
Fat (g)
Carbohydrate (g)
Ca (mg)
Na (mg)

Control drink

Protein drink

820
2
2
42
600
33

810
30
2
13
603
48
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Anthropometry and physical activity assessment
Anthropometric measurements were performed with subjects
in light clothes and without shoes. Standing height was
measured using a wall-mounted stadiometer (Veeder-Root,
Elizabethtown, NC, USA) to the nearest 0·1 cm. Body weight
was measured using an electronic scale (August Sauter
GmbH, D-7470 Albstadt 1 Ebingen, Germany) to the nearest
0·1 kg. Physical activity level was assessed by the International
Physical Activity Questionnaire short form (www.ipaq.ki.se).
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Dietary intakes
Dietary intake was assessed by a 3-d weighed food record
(2 week-days, one weekend day). Participants were asked to
record everything they ate and drank for three consecutive
days, using electronic food scales provided and household
measures. They watched a training video on how to complete
their food record before undertaking the food record. When
the food record was returned 1 week later, the participant
was interviewed to clarify the types and amount of food or
beverages recorded. The food record was analysed using the
AUSNUT99 database (Foodworks Professional edition version
3.02) by nutritionists trained in dietary assessment.

performed on sera stored at 2 808C, in a single batch to
reduce variability. Analyses of urinary sodium, potassium and
creatinine excretion were performed on urine stored at
2 208C, in a single batch.
Serum total cholesterol, HDL-cholesterol and TAG concentrations were analysed with a fully automated analyser
(Architect c16000; Abbott Laboratories, Abbott Park, IL,
USA). The assay CV were less than 0·6 % for total cholesterol,
2·2 % for TAG and 2·3 % for HDL-cholesterol. Serum LDLcholesterol was calculated using the Friedewald equation(21).
Serum glucose was measured using a hexokinase/G-6-PDH
method (Abbott Laboratories), using a fully automated analyser (Architect c16000). The assay CV was less than 1 %.
Serum insulin was analysed by immunoassay (Abbott Laboratories) using a fully automated analyser (Architect c16000),
with an assay CV of less than 1·5 %. The homeostasis model
assessment score was calculated with the following formula(22)
(serum glucose (mmol/l) £ serum insulin (mU/ml)/22·5), to
estimate changes in insulin sensitivity. Urinary sodium and
potassium concentrations were analysed using an ion-selective electrode with an automated analyser (Roche Hitachi
917; Castle Hill, New South Wales, Australia). The CV of the
sodium and potassium assays were , 2 %.

Adverse events
Blood pressure
Blood pressure was assessed using an automated sphygmomanometer (Critikon Dinamap 8100; Non-Invasive Blood
Pressure Monitor, GE Healthcare, Rydalmere, New South
Wales, Australia). Participants were seated for 5 min, relaxed
and not moving or speaking in a quiet temperature-controlled
(23 –248C) room. The left arm was supported at the level of
the heart and it was ensured that the arm was not constricted
by tight clothing. The measurements were repeated three
times at 1 min intervals and the average of the three measurements was entered into the database. Participants were
instructed not to take any medication in the morning before
blood pressure was measured.

Biochemistry
Venous blood samples were collected following a 12 h fast
from the antecubital vein of the forearm. Blood was collected
into BD Vacutainerw (BD Australian and New Zealand, North
Ryde, NSW, Australia) heparin or SST tubes. A 24 h urine collection was performed on the third day of the food recording
period in a 5 litre plastic collection bottle which contained
20 ml of 1 M -HCl. Participants were instructed to commence
on waking in the morning immediately following voiding
their bladder. All urine was then collected for 24 h, with
the final sample in the morning on waking the next day.
All biochemical analyses were performed in the PathWest
Laboratory at the Royal Perth Hospital, Perth, Western
Australia. Analyses of glucose were performed on plasma
samples within 4 h of collection, which were centrifuged
within 30 min after the blood was taken and transported to
the laboratory on ice. Analyses of lipids and insulin were

Using a previously validated method(23), participants were
asked to fill out an adverse-event diary in which each contact
with a physician was recorded. At 6-month intervals, the diary
was returned to the study centre at clinic visit or by mail.
The adverse events were coded using the International
Classification of Primary Care (ICPC2 Plus) system database
of disease coding, a validated method of event recording
developed for use in general practice(24).

Statistical analysis
Statistical analyses were performed using SPSS 17.0 software
(SPSS, Inc., Chicago, IL, USA) or SAS 9.2 software (SAS
Institute, Cary, NC, USA). Power calculations were performed
before the commencement of the study. For at least 80 %
power and 5 % level of significance, a sample size of 100 participants in each group was required to detect a difference of
3 mmHg in systolic blood pressure. We assumed a standard
deviation of the difference of 10 mmHg based on our previous
studies, two post-baseline measurements (at year 1 and year 2)
and a correlation between measures of 0·65. The primary analysis was intention-to-treat. The intention-to-treat population
was defined as all participants randomised to the study, for
which there were baseline measurements. In this analysis,
there was no replacement of missing data. Therefore, the
number of data points included in the analysis depended on
the number of participants and measurements at each time
point for the parameter of interest. Per-protocol analysis was
also performed. The per-protocol analysis included participants who: completed the 2-year trial; consumed at least
70 % of the supplements provided during both year 1 and
year 2; and did not alter their antihypertensive medication

Protein intake and blood pressure
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Phone screen (n 829)
Excluded (n 573)
– Inclusion criteria not met (n 327)
– Declined to participate (n 247)
– Other reasons (n 12)
Clinic screen (n 256)
Excluded (n 37)
– Inclusion criteria not met (n 22)
– Declined to participate (n 15)
Randomised (n 219)

Baseline: protein (n 109)

Intention-to-treat
population

Withdrawn (n 15)
– Personal reasons (n 11)
– Medical reasons (n 4)

Withdrawn (n 8)
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Baseline: control (n 110)

– Personal reasons (n 5)
– Medical reasons (n 3)

Year 1: measurements (n 95)

Year 1: measurements (n 101)

Withdrawn (n 8)

Withdrawn (n 7)

– Personal reasons (n 3)
– Medical reasons (n 5)

– Personal reasons (n 4)
– Medical reasons (n 3)

Year 2: measurements (n 93)

Completed
the trial

Year 2: measurements (n 88)

Excluded (n 38)

Excluded (n 39)

– Consumed <70% of
supplements (n 18)
– Changed antihypertensive
medication (n 17)
– Both of the above (n 3)

– Consumed <70% of
supplements (n 21)
– Changed antihypertesive
medication (n 12)
– Both of the above (n 6)

Year 2: measurements (n 55)

Per-protocol
population

Year 2: measurements (n 49)

Fig. 1. Flow chart of participants.

during the trial. For descriptive data, results are presented as
means and standard deviations except for insulin and TAG
which were log-transformed and are reported as geometric
mean and 95 % CI. The baseline-adjusted between-group
differences are presented as mean (95 % CI), with P,0·05 in
a two-tailed test set as the level of significance. At baseline,
characteristics of participants in the two groups, including
nutrient intakes, were compared using the independentsamples t test and the x 2 test for categorical variables.
At year 1 and year 2, differences between groups in nutrient
intakes were analysed using univariate general linear models
with adjustment for baseline values. The PROC MIXED

procedure in SAS was used to assess baseline-adjusted
between-group differences in blood pressure during the
2-year intervention, and specifically at year 1 and year 2.
Models used included fixed effects of baseline value, treatment group, time and a treatment group £ time interaction
term. Between-group differences were also adjusted for
potential confounding factors, including age, body weight,
alcohol intake, and urinary sodium and potassium excretion,
which were included as covariates in the models. Separate
sub-group analyses of blood pressure differences in women
with systolic blood pressure greater than 140 mmHg at baseline were also performed using mixed-effects models.
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Results
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Participants and baseline characteristics
A total of 219 women (110 in the control group and 109 in the
protein group) aged 70 –80 years were randomised and commenced the study. Of these, 196 (ninety-five control, 101 protein; 89·5 %) women had measurements taken at the end of
year 1, and 181 women (eighty-eight control, ninety-three
protein; 82·6 %) had measurements taken at the end of year
2 (Fig. 1). The two groups were well matched at baseline,
and there were no significant differences between groups in
baseline characteristics (Table 2). The groups were also well
matched according to use of specific classes of antihypertensive medications. In the control group, thirteen were taking
an angiotensin-converting enzyme inhibitor; eighteen, an
angiotensin II receptor blocker; nine, a calcium channel
entry blocker; eight, a b-blocker; and six, a diuretic. In the
protein group, nine were taking an angiotensin-converting
enzyme inhibitor; eighteen, an angiotensin II receptor blocker;
nine, a calcium channel entry blocker; nine, a b-blocker;
and eleven, a diuretic. There were no significant differences
between groups in the use of specific classes of antihypertensive medications.
Among the 196 participants who completed the trial to the
end of year 1, compliance with the assigned supplement
was 78 (SD 29) % for protein and 72 (SD 31) % for control.
Among the 181 participants who completed the trial to the
end of year 2, compliance with the assigned supplement
was 88 (SD 25) % for protein and 81 (SD 25) % for control.
The baseline characteristics of the participants who withdrew
from the trial were not significantly different from those who
completed the trial. There were no reported adverse effects
from consuming either the control or the protein beverages
during the 2-year study.

Energy, nutrient intake and physical activity
Body weight, energy and nutrient intakes and physical activity
levels were well matched between groups at baseline
(Table 3). Estimated energy intakes at baseline, year 1 and
year 2 were not significantly different between groups. For
protein relative to control, the estimated mean (95 % CI) net
differences in protein and carbohydrate intakes were 18
(13, 23) and 2 22 (2 9, 2 35) g/d at year 1, and 22 (17, 28)
and 218 (2 6, 2 31) g/d at year 2. At year 1, the sodium
and potassium excretion was not different between groups,
but at year 2, potassium excretion was higher for protein compared to control. There was a similar non-significant trend for
sodium such that the sodium:potassium ratio was not different
between groups (Table 3).

Blood pressure
The mean systolic and diastolic blood pressures were well
matched between the groups at baseline (Table 2). The
mean baseline-adjusted blood pressures in each group
during the 2-year intervention and specifically at year 1 and
year 2 are presented in Table 4. There were no significant

differences in systolic or diastolic blood pressures between
groups at year 1 or year 2.
A per-protocol analysis included 104 women (Fig. 1) who
completed the 2-year trial, did not alter their antihypertensive
medication, and consumed at least 70 % of the supplements
during the trial. For protein relative to control, the overall
differences in systolic and diastolic blood pressures were 0·6
(2 2·1, 3·2) mmHg, P¼ 0·68 and 0·1 (2 1·9, 2·2) mmHg,
P¼0·90, respectively. Net differences in systolic and diastolic
blood pressures were 22·9 (2 7·0, 1·3) mmHg, P¼0·18 and
2 1·8 (2 4·8, 1·3) mmHg, P¼ 0·26 at year 1, and 3·3 (21·0,
7·5) mmHg, P¼ 0·12 and 1·6 (22·5, 3·0) mmHg, P¼0·85 at
year 2. Adjustment for age, body weight, alcohol intake, and
urinary sodium and potassium excretion, did not alter
interpretation of the results.

Discussion
We aimed to investigate the long-term effects on blood
pressure of a diet higher in protein. A total of 219 women
aged 70 – 80 years were recruited to this trial. In the intention-to-treat and per-protocol analyses, there were no significant differences observed in either systolic or diastolic blood
pressure between groups.
Hypertension is the leading risk factor for total and CVD
mortality and is responsible for 13 % of deaths globally(25).
It currently affects more than one-quarter of the world’s population(26), and often more than half of all men and women
aged over 70 years(27,28). In the present study, the prevalence
of hypertension, defined as those receiving antihypertensive
medication or with systolic blood pressure at baseline greater
than 140 mmHg, was 70 %. The worldwide prevalence of
Table 2. Characteristics of the women in the control and protein groups
at baseline*
(Mean values and standard deviations or geometric means and 95 %
confidence intervals)

Age (years)
Height (m)
Body weight (kg)
BMI (kg/m2)
Antihypertensive medication (%)
Systolic pressure (mmHg)
Diastolic pressure (mmHg)
Total cholesterol (mmol/l)
LDL-cholesterol (mmol/l)
HDL-cholesterol (mmol/l)
TAG (mmol/l)
Geometric mean
95 % CI
Glucose (mmol/l)
Insulin (mU/l)
Geometric mean
95 % CI
HOMA-IR (units)

Control (n 110)

Protein (n 109)

Mean

SD

Mean

SD

74·3
1·60
69·7
27·2
52
142·9
70·1
5·66
3·28
1·74

2·6
0·06
11·5
3·9

74·3
1·60
67·4
26·3
50
142·9
69·6
5·73
3·35
1·79

2·7
0·06
11·1
3·8
50
17·5
11·9
1·12
1·01
0·40

15·6
10·8
0·97
0·86
0·40

1·31
1·21, 1·40
5·32
0·50

1·18
1·09, 1·28
5·28
0·49

8·05
7·41, 8·76
2·1
0·9

7·18
6·60, 7·80
1·9
0·9

HOMA-IR, homeostasis model assessment-insulin resistance.
* Between-group differences analysed using the independent-samples t test and
the x 2 test for categorical variables. There were no significant differences
between groups for any of the variables reported.
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Table 3. Mean body weight, energy and nutrient intakes and physical activity levels of the women in the control and protein groups at baseline, year 1 and year 2
(Mean values and standard deviations)
Control
Baseline (n 110)

Year 1 (n 92)

Year 2 (n 87)

Baseline (n 108)

Year 1 (n 96)

Year 2 (n 93)

Mean

SD

Mean

SD

Mean

SD

Mean

SD

69·7
7058

11·5
1422

70·6
7595*

11·7
1717

69·7
7184

11·4
1435

67·4
7075

11·1
1517

61
32

20
6

66*
32

23
6

60
31*

17
5

63
33

19
5

64
32*

24
6

62
31†

20
6

75
1·1
19

16
0·3
3

75
1·1
17†

17
0·3
3

73
1·1
18*

17
0·4
3

75
1·1
19

18
0·3
4

93†,‡
1·4†‡
22†‡

19
0·4
4

96†,‡
1·4†‡
23†‡

20
0·4
5

53
6
7

183§
41†‡
21*

52
6
7

10·3
3·5
47
19
379
389

6·7
2·6
117
69*§
1364†
385

9·7
3·9
42
20
413
356

189
46
22

42
7
7

211†
46
20‡

50
6
6‡

203*
46
20*

48
6
6

6·8
2·7
100
57
1021
443

10·2
4·0
43
21
439
386

6·3
2·4
109
62
1414†
441

9·2
3·5
47
22
453
394

5·7
2·2
103
59
1377†
424

7·9
3·1
37
21
411
406

184
45
23
7·1
2·8
111
62
978
374

44
6
7
10·7
4·2
53
23
376
363

Mean
67·4
7381

187‡
41†‡
19†
5·6
1·9
116
65
1347†
429

SD

11·7
1904

Mean
67·5
7317

SD

11·4
1717

Protein intake and blood pressure

Body weight (kg)
Energy (kJ/d)
Total fat
g/d
% of energy
Protein
g/d
g/kg body weight per d
% of energy
Carbohydrate intake
g/d
% of energy
Fibre (g/d)
Alcohol
g/d
% of energy
Na excretion (mmol/d)
K excretion (mmol/d)
Ca intake (mg/d)
Activity (Met-min/week)

Protein

* Mean values were significantly different from that at baseline (P, 0·01).
† Mean values were significantly different from that at baseline (P, 0·001).
‡ Mean values were significantly different from that of the control group at the same time point (P,0·001).
§ Mean values were significantly different from that of the control group at the same time point (P,0·01).
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Table 4. Mean baseline-adjusted systolic and diastolic blood pressures of the women in the protein and control groups during
the 2-year intervention and specifically at year 1 and year 2 of the trial*
(Mean values and 95 % confidence intervals)
Control

Overall‡
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Year 1
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Year 2
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)

Protein

Difference

Mean

95 % CI

Mean

95 % CI

Mean

95 % CI

P†

134·2
67·4

132·1, 136·3
65·9, 68·9

133·9
66·7

131·9, 136·0
65·2, 68·1

2 0·3
2 0·7

2 3·2, 2·7
2 2·8, 1·4

0·86
0·50

135·7
67·1

133·5, 137·8
65·6, 68·6

133·4
65·5

131·3, 135·5
64·1, 67·0

2 2·3
2 1·5

2 5·3, 0·7
2 3·6, 0·6

0·14
0·15

133·0
67·6

130·7, 135·2
66·0, 69·2

134·6
67·8

132·4, 136·8
66·3, 69·4

1·6
0·3

2 1·5, 4·7
2 1·9, 2·4

0·30
0·82

British Journal of Nutrition

* Intention-to-treat population.
† P-value is for baseline-adjusted between-group differences analysed using mixed-effects models.
‡ Overall mean baseline-adjusted blood pressures and baseline-adjusted between-group differences during the 2-year trial.

hypertension is projected to rise considerably due to an
increase in prevalence in developing countries and an
increase in life expectancy in many of the populations(26).
The impact on blood pressure of advice to alter protein
intake in this population is unclear.
Lower blood pressure with higher protein intake is a consistent finding in population studies(3,4). In addition, a
reduction in blood pressure with protein compared with
carbohydrate is a consistent finding in previous short-term
randomised controlled trials(8 – 11). Although the population
data indicate the potential for greater benefits of plant protein(4,7), results of intervention studies indicate little difference
between plant and animal proteins in their effects on blood
pressure(13 – 16). In previous trials, the increases in protein
and decreases in carbohydrate have ranged from approximately 25 – 70 g/d and benefits on systolic blood pressure
have ranged from 1·4 to 5·9 mmHg, but a dose – response
relationship is not clear(8 – 11,29,30). In the only previous trial
to investigate the effects of animal protein specifically, as
lean red meat, on blood pressure, a lower systolic blood pressure of 4 mmHg was observed with protein (approximately
29 g/d or 5 % of energy) compared with carbohydrate control
after 12 weeks of intervention. A limitation in interpreting the
results of these intervention studies is that changes in blood
pressure may be the result of changes in both protein and
carbohydrate in the diet. In the present study, the increase
in protein intake was 30 g/d from the supplement, but was
estimated to be approximately 20 g/d from reported intake
data. The mean systolic blood pressure difference over the 2
years was less than 1 mmHg. The results were similar for
both the intention-to-treat and the per-protocol analyses.
Thus, available evidence suggests that partial substitution of
carbohydrate in the diet with protein can improve blood
pressure. However, these results have yet to be translated
into effective and widely applicable approaches for the prevention and treatment of high blood pressure. A possible
reason for this is that substantial substitution of carbohydrate
with protein can be difficult to achieve and sustain in longterm dietary intervention studies. Few longer-term trials have
been conducted, with the longest duration being 12

months(12,20). The present trial is the first to investigate the
longer-term effects over 2 years of increasing animal protein
specifically, relative to carbohydrate, on blood pressure.
In addition, our study did not involve energy restriction and
weight loss. Our results provide data on the potential longterm impact of advice to increase protein intake. Although
the trend observed at year 1 would be consistent with results
of previous trials(8 – 11,12,20,29,30), there was no overall effect on
blood pressure over the 2-year trial, and little difference
between groups at year 2.
There are several possible explanations for the lack of effect
of protein, relative to carbohydrate, in the present study. The
differences in protein and carbohydrate intakes were modest.
Although advice to increase protein and reduce refined
carbohydrate intakes is likely to result in modest increases in
protein intake, perhaps in the order of 20 – 30 g/d, the magnitude of this change may not be enough to substantially alter
blood pressure. Previous short-term trials have shown benefits
on blood pressure with often larger differences in protein
intake between groups(8 – 11). The high prevalence of the use
of antihypertensive medication and the change in medication
use during the trial may also have masked effects on blood
pressure. However, the similar estimates from the intentionto-treat and per-protocol analyses do not support this
argument. In addition, although the high prevalence of the
use of antihypertensive medication is a potential limitation
of our study, this prevalence is similar to many other populations, and thus our results are applicable to these populations. Another possibility is that the protein supplement
used (whey) could be less effective than other forms of
protein. The short-term effects of whey protein on blood
pressure have yet to be studied. A further possibility is that
short-term effects are not sustained in the longer term. This
may relate to diminished compliance with time, but our data
from the per-protocol population suggest similar compliance
at year 1 and year 2.
An additional limitation of this study is the selection of
women over 70 years as the study population. Previous
studies to have investigated the effects of dietary protein
relative to carbohydrate on blood pressure have recruited
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primarily men and women less than 70 years(8 – 12). Both shortterm and longer-term effects of protein on blood pressure
have not been previously investigated in an elderly population. Ageing is characterised by changes in the nervous
and hormonal systems involved in the regulation of blood
pressure(31). Therefore, conclusions based on the results
of our study must take into account that older individuals
compared to younger individuals may exhibit a different
blood pressure response to an increase in protein intake.
Furthermore, older men were not recruited to our study.
Sex differences in regulation of blood pressure could also
influence responsiveness to dietary changes(32).
In conclusion, we have shown that modest differences in
protein intake, derived from whey, and carbohydrate intake,
do not significantly influence blood pressure over 2 years.
These results do not support the proposal that a higher
whey protein intake in older women can have prolonged
effects on blood pressures relative to carbohydrate intake.
Additional prospective population studies and long-term
randomised controlled trials are needed to investigate the
potential long-term impact of higher protein intakes.
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